Risk prediction model for relapse of anti-synthetase syndrome-associated interstitial lung disease in Japanese multicentre MYKO cohort study
Authors' conclusion
Our multicentre cohort study showed that the RPM model using the presence of acute/subacute ILD and %FVC values was a useful tool for stratifying risk of ASyS-ILD relapse.
Study context
- Population
- Patients with ASyS-ILD treated with prednisolone and calcineurin inhibitors as remission induction therapy, Japanese multicentre MYKO cohortof 487 with IIM, 1991–2024
- Participants
- 101 patients
- Outcome
- Relapse of ASyS-ILD after remission induction therapy (risk factors and risk prediction model)
Methodological detailsmultivariate Cox regression, ROC analysis, Tacrolimus used by 81.2% and ciclosporin by 18.8% as calcineurin inhibitors for remission induction
- Multivariate Cox regression
- ROC analysis
- Tacrolimus used by 81.2% and ciclosporin by 18.8% as calcineurin inhibitors for remission induction
Main finding
As reported in the abstract
Relapse of ASyS-ILD · median follow-up 4.3 years
Patients who relapsed
39
38.6%
5-year relapse rate
45.1%
%forced vital capacity (FVC) cut-off for poor prognosis (ROC analysis)
≤77%
Observational data: associations, not effects.
Original publication
Risk prediction model for relapse of anti-synthetase syndrome-associated interstitial lung disease in Japanese multicentre MYKO cohort study. Rheumatology (Oxford). Published 5 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →